By Mill Chart
Last update: Jun 30, 2025
EXELIXIS INC (NASDAQ:EXEL) was identified by our screener as a strong growth stock with a favorable technical setup. The company combines solid fundamentals with a promising price pattern, making it worth a closer look for investors seeking growth opportunities.
EXELIXIS stands out with an 8/10 Growth Rating, supported by:
The company also scores well on profitability (8/10) and financial health (9/10), with no debt and strong margins.
The stock shows a bullish technical structure:
Volume has increased recently, suggesting growing investor interest.
Despite strong growth, EXEL appears reasonably valued:
Our Strong Growth Stocks with Good Technical Setup screener lists more candidates with similar traits.
For deeper analysis, review the full fundamental report and technical report.
This is not investment advice. Always conduct your own research before making decisions.
43.67
+0.58 (+1.35%)
Find more stocks in the Stock Screener
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support levels, suggesting a potential breakout opportunity.
EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.
Wondering what's happening in Monday's pre-market session? Find an overview in this article.
EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, growth, and financial health, making it a compelling pick for value investors.